Elad Sharon named clinical and translational director of Immunotherapy Toxicity Service at Dana-Farber

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.

November 15, 2024

Vol.50 No.43

Clinical Roundup

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

New research on the possibility to kill TNBCs by hijacking signals that normally drive mammary gland involution was released in Nature.

October 11, 2024

Vol.50 No.38

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

In Brief

Cigall Kadoch wins $250,000 Blavatnik National Award

Cigall Kadoch was named the laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences for her work in cancer biology.

September 20, 2024

Vol.50 No.35

Tumors are able to form with no DNA mutations, fly study shows

Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.

September 13, 2024

Vol.50 No.34

By Jacquelyn Cobb